SARS-CoV-2冠状病毒核衣壳蛋白的结构生物学研究进展  

Progresses in structural biology of SARS-CoV-2 nucleocapsid protein

作　　者：李潇 徐浩 于佳鑫 林东海[1] 郭晨云[1] LI Xiao;XU Hao;YU Jiaxin;LIN Donghai;GUO Chenyun(Department of Chemical Biology,College of Chemistry and Chemical Engineering,Xiamen University,Xiamen 361005,China)

机构地区：[1]厦门大学化学化工学院化学生物学系,厦门361005

出　　处：《生命的化学》2022年第6期1051-1056,共6页Chemistry of Life

基　　金：福建省自然科学基金项目(2020J01022)。

摘　　要：严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)引发的新冠肺炎(COVID-19)严重威胁着全球人类健康,研发特异性抗新冠肺炎药物迫在眉睫。在SARS-CoV-2病毒中,核衣壳蛋白含量最丰富,而且保守性高,它不仅可以将SARS-CoV-2基因组RNA组装成与病毒复制和繁殖密切相关的核糖核蛋白(RNP)复合物,还可以调控宿主细胞的免疫功能,是一个重要的药物靶标。本文综述了SARS-CoV-2病毒核衣壳蛋白的结构特征及其与RNA和其他蛋白质的相互作用,以及核衣壳蛋白在临床研究中的应用,以期为新冠肺炎的治疗提供新的药物靶点。The outbreak of novel coronavirus pneumonia(COVID-19)caused by severe acute respiratory syndrome coronavirus type 2(SARS-CoV-2)has triggered a global health crisis,and there is an urgent need for developing effective drug to resist SARS-CoV-2.Among the SARS-CoV-2 viral proteins,nucleocapsid protein is the most abundant and its amino acid sequence is highly conserved.It can pack SARS-CoV-2 genomic RNA into ribonucleoprotein(RNP)complexes,which is closely related to viral replication and reproduction.Moreover,nucleocapsid protein can also disturb the immune responses of host cell.Therefore,nucleocapsid protein is an important drug target against COVID-19.This paper reviews the structural characteristics of SARS-CoV-2 nucleocapsid protein and its interaction with RNA and other proteins,as well as applications of nucleocapsid protein in clinical research.This review provides a novel potential drug target for the treatment of COVID-19.

关 键 词：SARS-CoV-2 核衣壳蛋白 结构特征 相互作用 药物靶标 

分 类 号：R373[医药卫生—病原生物学]